Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Aug 5, 2014
Sangamo BioSciences Announces Presentation At The 2014 Wedbush Securities Life Sciences Management Access Conference

Aug 5, 2014
Five Sangamo Scientists Recognized By Thomson Reuters Among Most Highly Cited Researchers Worldwide Of 2014


Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
13.65
Change:
+ 0.38
Day High:
13.71
Day Low:
13.11
Volume:
295,400
1:21 PM ET on Aug 22, 2014

Shareholder Tools